Cancer Biomarkers Market Research Report 2018 to 2023 | ABBOTT LABORATORIES, AFFYMETRIX, (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC, ROCHE HOLDING AG, 23ANDME, AMBRY GENETICS

Cancer Biomarkers Market Highlights
The global cancer biomarkers market is expected to register a good CAGR during the forecast period of 2018u20132023. Biomarkers are chemical, physical or biological parameters, which can be used to indicate disease states. Oncology biomarkers offer high speed, non-invasive cancer diagnosis, and are believed to enhance cancer detection and screening. Major driving factors for the market are streamlined drug delivery process, noninvasive technology, and increased rates of survival.

Get your sample report now @ https://marketprognosis.com/sample-request/16889
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

United States Leads the Market
The United States cancer biomarker market held the largest market share in 2017 in the North America region due to the presence of high-quality healthcare system, and the high rate of prevalence of cancer. In the Asia-Pacific sector, China and India have been identified as potential emerging markets.

Key Developments in the Market
• January 2018: Roche and GE entered into a partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment. This partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics, and sequencing portfolio.
• January 2018: New biomarkers found for colorectal cancer (MYO5B).
• November 2017: Researchers found a new biomarker for breast cancer (GIRK1).
• October 2017: ABBOTT acquired ALERE.
• September 2017: Roche announced its progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress.

Major Players:
ABBOTT LABORATORIES, AFFYMETRIX INC., (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC INC., ROCHE HOLDING AG, 23ANDME, AMBRY GENETICS, BIOMERIEUX, CELERA CORPORATION (QUEST DIAGNOSTICS), and ILLUMINA INC., among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/16889
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increased Incidences of Cancer Driving the Market
Cancer is one of the leading causes of death across the globe, with 8.8 million victims in 2015, accounting for nearly one in six deaths. The disease has witnessed significant growth in the last few decades and is expected to grow rapidly during the forecast period. There were 10.9 million new cases in 2002, which increased to 14.1 million in 2012. This is approximately a 30% growth in a decade. The WHO expects this number to increase to 70% over the next two decades. This increased incidence of various diseases is expected to drive the global market, as biomarkers have a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.
According to WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low and middle-income countries has the necessary data to drive cancer policy. This lack of data has been a limiting factor for many years, but the trend is changing. As data is being generated aggressively in the healthcare sector, the lack of data has already become outdated in a few developing countries, and it will likely become so in the remaining countries. This augmentation of data is expected to provide the basis for any national policy on cancer. In turn, this will possibly lead to an increase in the percentage of people opting for cancer treatment. This improved demand in low and middle-income countries is projected to boost the cancer biomarker market. The other factors, such as paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis and increasing usage in drug development are driving the global cancer biomarker market.

High Cost of Diagnosis
According to a recent publication, approximately 13% of all deaths across the globe are caused due to cancer. It is estimated that the total cost of cancer in the United States was more than USD 263 billion in a single year. The usage of biomarkers for screening, monitoring, diagnosing, and optimizing treatment has the potential to improve patient outcomes. On the contrary, the discovery of cancer biomarkers and the development and validation of assays are both complex and expensive. Because of the critical role that biomarkers play at all stages of the disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation, and assessment of clinical utility, before incorporation into routine clinical care. All these processes add up to the actual cost of cancer biomarkers and make them expensive. Due to these reasons, biomarker development and validation costs are higher today. This applies particularly to the cancer field with the advent of novel cancer biomarkers. The costs of many of these new-generation technologies, like prognostic or predictive biomarkers, run into thousands of dollars per patient. This high cost of diagnosis, reimbursement issues, and need for immediate processing are hindering the market.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/16889
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.